Logo image
Reducing the Burden of Hypoglycemia in Type 1 Diabetes: The Impact of FLO23011 on Patient-Reported Outcomes and Glycemic Correlates of Treatment Response
Journal article   Open access   Peer reviewed

Reducing the Burden of Hypoglycemia in Type 1 Diabetes: The Impact of FLO23011 on Patient-Reported Outcomes and Glycemic Correlates of Treatment Response

David Russell-Jones, Eliza G Meehan, Vera Smout, Sabyasachi Roy, Wendy Frost, Tim M Young and David B Bartlett
Diabetes therapy
02/11/2026
PMID: 42970212

Abstract

Continuous glucose monitoring FLO23011 Beta-hydroxybutyrate Hypoglycemia recovery Patient-reported outcomes Hypoglycemia Type 1 diabetes
The aim of this study was to compare patient-reported outcomes (PROs) related to hypoglycemia recovery with FLO23011, a novel multi-energy substrate for hypoglycemia (MESH) recovery drink combining 15 g glucose with beta-hydroxybutyrate (BHB), versus standard glucose gel in adults with type 1 diabetes, and to explore associations between continuous glucose monitoring (CGM)-derived metrics and perceived and objective treatment response. In a randomized, open-label, crossover study, 12 adults with type 1 diabetes used FLO23011 and standard glucose gel to treat hypoglycemia for two 6-week periods, with continuous glucose monitoring throughout. PROs were assessed using a study-specific 14-domain questionnaire and exit interviews. Exploratory CGM analyses examined patient-relevant recovery signals: glucose-band exposure versus psychological PRO scores, and baseline glycemic variability versus time-in-range (TIR) response. FLO23011 was rated more favorably than glucose gel in 13/14 domains. Among recovery-related items, 70% preferred FLO23011 for reduced aftereffects and 80% for return to daily activities; 82% preferred FLO23011 for sense of control, 73% for dosing confidence, and 64% for overall hypoglycemia management. In exit interviews, 92% rated FLO23011 "very/extremely" effective and 92% reported "never" or "rarely" experiencing post-hypoglycemia hangover symptoms with FLO23011. Participants described faster cognitive recovery, reduced disruption, and greater confidence. In exploratory analyses, reduced Level 1 hypoglycemia exposure was associated with higher reduced-worry and management-ability ratings (n = 5; ρ = 0.90; P = 0.037). Higher baseline coefficient of variation (CV) was associated with greater TIR improvement with FLO23011 (n = 9; ρ = 0.917; P = 0.0005). FLO23011 was associated with more favorable patient-reported hypoglycemia recovery than glucose gel, with participants reporting benefits for aftereffects, daily functioning, and confidence. In exploratory CGM-PRO analyses, strong correlations in small subsets suggested that perceived benefit aligns with reduced Level 1 hypoglycemia exposure, and that baseline glycemic variability may predict objective response. These findings support evaluating hypoglycemia treatments on patient-reported recovery alongside glycemic outcomes. A graphical abstract is available with this article. ISRCTN Registry, ISRCTN19855666. Retrospectively registered, 11 June 2026.
url
https://doi.org/10.1007/s13300-026-01929-6View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image

Usage Policy